Hasil Pencarian - Quincy Chu

  • Menampilkan 1 - 11 hasil dari 11
Perbaiki Hasil
  1. 1
    Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada

    Impact of Adjuvant Atezolizumab on Recurrences Avoided and Treatment Cost Savings for Patients with Stage II-IIIA Non-Small Cell Lung Cancer in Canada oleh Quincy Chu, Kaushik Sripada, Sarah Vaselenak, Nick Jovanoski, Melina Arnold

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors

    Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors oleh Lei Zhang, Quincy Chu, John Coffin, Kim Formenti, Iyare Izevbaye

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Rapid atrophy of cardiac left ventricular mass in patients with non‐small cell carcinoma of the lung

    Rapid atrophy of cardiac left ventricular mass in patients with non‐small cell carcinoma of the lung oleh Seyyed Mohammad Reza Kazemi‐Bajestani, Harald Becher, Charles Butts, Naveen S. Basappa, Michael Smylie, Anil Abraham Joy, Randeep Sangha, Andrea Gallivan, Peter Kavsak, Quincy Chu, Vickie E. Baracos

    Diterbitkan 2019-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer

    The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer oleh Barbara Melosky, Parneet Cheema, Rosalyn A. Juergens, Natasha B. Leighl, Geoffrey Liu, Paul Wheatley-Price, Adrian Sacher, Stephanie Snow, Ming-Sound Tsao, Deanna McLeod, Quincy Chu

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience

    Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience oleh Martin Rupp, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, Shoghag Khoudigian, Arushi Sharma, Phu Vinh On, Geoffrey Liu

    Diterbitkan 2023-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process

    Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process oleh James Tankel, Jonathan Spicer, Quincy Chu, Pierre Olivier Fiset, Biniam Kidane, Natasha B. Leighl, Philippe Joubert, Donna Maziak, David Palma, Anna McGuire, Barbara Melosky, Stephanie Snow, Houda Bahig, Normand Blais

    Diterbitkan 2023-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)

    695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy... oleh Rakesh Kumar, Keunchil Park, Frances A Shepherd, John V Heymach, Quincy Chu, Sylvia Hartl, J Carl Barrett, Sonia Iyer, Parneet Cheema, Marianna Koczywas, Maximilian Hochmair, Giuseppe Galletti, Mark Gustavson, Brent Evans, Jan Cosaert

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial

    347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial oleh Lucy Gilbert, Jameel Muzaffar, David McDermott, Vamsidhar Velcheti, Anna Spreafico, Valentina Boni, Christopher Hoimes, Ira Winer, Seth Rosen, Quincy Chu, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Piotr Tomczak, Debora Bruno, Elizabeth Dorn, Jessicca Rege

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced solid malignancies

    741 TWT-101: a first-in-clinic study of CFI-402411, a hematopoietic progenitor Kinase-1 (HPK1) inhibitor, as single agent or combined with pembrolizumab in subjects with advanced s... oleh Omid Hamid, Siqing Fu, Manish Sharma, Anna Spreafico, Kyriakos P Papadopoulos, Erika Hamilton, Alexander Spira, Quincy Chu, Brigette Ma, Emily Roberts-Thomson, Dih-Yih Chen, Judy S Wang, Scott A Laurie, Mark R Bray, Roger Sidhu

    Diterbitkan 2023-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database

    Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Datab... oleh Heidi A. I. Grosjean, Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb, Don G. Morris, Winson Y. Cheung, Aliyah Pabani

    Diterbitkan 2021-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study

    BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study oleh Quincy Chu, MD, Natasha B. Leighl, MD, Veerle Surmont, MD, Carla van Herpen, MD, PhD, Anne Sibille, MD, Ben Markman, MD, Stephen Clarke, MD, Rosalyn A. Juergens, MD, PhD, Mirelis Acosta Rivera, MD, Vladimir Andelkovic, MD, Charles M. Rudin, MD, PhD, Stephanie Snow, MD, Dong-Wan Kim, MD, Michael Sanatani, MD, Hongxia Lin, PhD, Kinjal Sanghavi, PhD, Sarah Tannenbaum-Dvir, MD, Paul Basciano, MD, Deanne Lathers, PhD, Katarzyna Urbanska, PhD, Georgia Kollia, PhD, Chunsheng He, PhD, Andrew DiPiero, BS, Yu Liu, MD, PhD, Neal Ready, MD, PhD

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: